Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AXDX

AXDX - Accelerate Diagnostics Inc Stock Price, Fair Value and News

$1.750.00 (0.00%)
Market Closed

3/100

AXDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

3/100

AXDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.4

Target 3M

$1.57

Target 6M

$1.49

AXDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXDX Price Action

Trailing 12 Months

-91.2%

AXDX RSI Chart

AXDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXDX Valuation

Market Cap

44.1M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

3.77

EV/EBITDA

-0.62

Price/Free Cashflow

-1.81

AXDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.4

Target 3M

$1.57

Target 6M

$1.49

AXDX Fundamentals

AXDX Revenue

AXDX Earnings

AXDX Profitability

Free Cashflow Yield

-55.19%

AXDX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202412.2M12.2M11.9M11.7M
202312.6M11.7M12.0M12.1M
202212.2M13.3M13.1M12.8M
202111.3M12.0M11.5M11.8M
20209.9M10.2M11.5M11.2M
20196.6M6.7M7.6M9.3M
20184.4M5.4M6.0M5.7M
2017613.0K1.3M2.1M4.2M
2016224.0K226.0K229.0K246.0K
2015122.0K127.0K132.0K75.0K
201446.0K52.0K55.0K122.0K
201380.0K41.0K48.2K48.0K
2012241.7K238.8K236.0K158.0K
201100244.5K243.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About Accelerate Diagnostics Inc

AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
 CEO
 WEBSITEhttps://acceleratediagnostics.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES179

Accelerate Diagnostics Inc Frequently Asked Questions

AXDX is the stock ticker symbol of Accelerate Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Accelerate Diagnostics Inc is 44.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AXDX's fair value in chart for subscribers.

The fair value guage provides a quick view whether AXDX is over valued or under valued. Whether Accelerate Diagnostics Inc is cheap or expensive depends on the assumptions which impact Accelerate Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXDX.

As of Tue Jan 27 2026, AXDX's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 3.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXDX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Accelerate Diagnostics Inc has provided -1 (multiply by 100 for percentage) rate of return.